A couple of years ago, when everyone was talking about stocks for 2024, I remember there were three sectors that kept making noise: technology, pharmaceuticals, and semiconductors. Now that we're in 2026, it's interesting to look back and see which predictions came true.

At that time, the stock market was in a clear bullish phase. The economic recovery was consolidating, and inflation had already decreased significantly. Many analysts pointed out that the reduction in interest rates could boost certain sectors more than others.

Alphabet was one of those names that was constantly in the spotlight. The company had that ecosystem of iconic brands - Google, YouTube, Android, Chrome - which allowed it to generate over 80% of its revenue through digital advertising. The interesting part was that they were also fully engaged in the AI race with Gemini, trying to compete with ChatGPT. In January 2024, its P/E ratio hovered around 29, making it seem more attractive than other tech giants.

Nvidia was another name that couldn't be ignored. They controlled nearly 90% of the AI chip market. Nvidia's shares had grown 239% in 2023, so the expectation was that this momentum would continue. Their dominant position in GPUs and expansion into gaming and automotive seemed solid.

In the pharmaceutical sector, Novo Nordisk was on the radar for its focus on obesity medications. With Ozempic gaining popularity and projections that the anti-obesity market would reach $44 billion by 2030, it had a pretty clear growth runway. In 2023, they showed a 29% increase in net sales.

Berkshire Hathaway represented the more conservative side of the equation. With Warren Buffett at the helm and $157 billion in cash, it offered stability. Its beta of 0.64 meant it experienced less volatility than the overall market, making it attractive for investors seeking peace of mind.

And then there was Broadcom, which had just acquired VMware. That strategic move positioned them beyond semiconductors, giving them exposure to enterprise software. They had grown 108% in 2023.

The reality is that the way investors approached these stocks in 2024 varied greatly depending on their time horizon. Short-term traders played with CFDs, taking advantage of volatility caused by interest rate changes, geopolitical conflicts, and central bank movements. It was speculative, risky, but potentially profitable.

Medium- and long-term investors, on the other hand, needed to focus on solid fundamentals, real diversification, and resistance to daily noise fluctuations. That meant not concentrating everything in a single stock but spreading risk across different sectors.

What turned out to be interesting afterward is that most of these names indeed continued to grow, albeit at different paces. The AI bet proved to be more than just a passing hype. The obesity pharmaceutical sector kept expanding. And diversified conglomerates like Berkshire maintained their stability.

If someone asks you now what the best stocks to invest in that 2024 window were, the likely answer is that a balanced portfolio combining Alphabet and Nvidia for tech growth, Novo Nordisk for pharmaceutical exposure, Berkshire for stability, and Broadcom for specialized semiconductors would have worked quite well. It wasn't exact science, but diversification across sectors and risk profiles definitely made a difference.